Cell permeable inhibitor of sirtuin 2 (SIRT2) (IC50=35μM). Promotes inclusion formation in cellular models of both Huntington’s disease and Parkinson’s disease. Prevents huntingtin-mediated proteasome dysfunction and reduces α-synuclein-mediated toxicity.
Product Details
| Alternative Name: | CPNQ, 5-[4-(4-Chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline |
| |
| Formula: | C20H17ClN4O3 |
| |
| MW: | 396.8 |
| |
| CAS: | 115687-05-3 |
| |
| Purity: | ≥95% |
| |
| Identity: | Determined by MS, 1H- and 13C-NMR. |
| |
| Appearance: | Yellow solid. |
| |
| Solubility: | Soluble in DMSO (>5mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Protect from light and oxygen. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington’s and Parkinson’s diseases: R.A. Bodner, et al.; PNAS
103, 4246 (2006),
Abstract;
Full Text
Related Products
